NASDAQ · RVPHW
Reviva Pharmaceuticals Holdings, Inc.
Healthcare · Biotechnology
$0.00
Down-$0.00 (-16.67%)
Updated Aug 23, 2026, 12:56 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 412.69K
- P/E ratio
- -1.25
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 303.38K
- Avg. volume
- 74.07K
Price performance
RVPHW price history
1M range · 0 trading sessions · Daily adjusted prices
RVPHW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest RVPHW news
The latest Smart Investors Daily articles mentioning RVPHW.
Stock researchCompany · Overview
RVPHW research
Overview
Company profile and research snapshot.
Company profile
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
